1090904-48-5

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 3-AMINOCYCLOBUTYLCARBAMATE is used as a reactant for the preparation of spirocyclic compounds that act as HAT inhibitors. These inhibitors are valuable in the development of drugs targeting histone acetyltransferases, which play a crucial role in the regulation of gene expression and have implications in various diseases, including cancer and neurodegenerative disorders.

Upstream product

• 871014-18-5 tert-butyl (trans-3-azidocyclobutyl)carbamate 
• 1239589-57-1 tert-butyl (cis-3-azidocyclobutyl)carbamate 
• 871014-17-4 trans-3-[(tert-butoxycarbonyl)amino]cyclobutyl methanesulfonate 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 1505373-63-6 tert-butyl (3-(benzylamino)cyclobutyl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1239589-55-9 tert-butyl {trans-3-[(4-nitrobenzoyl)amino]cyclobutyl}carbamate 
• 1246739-82-1 tert-butyl N-[3-(pyrrolidin-1-yl)cyclobutyl]carbamate 

Relevant academic research and scientific papers

ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS

Provided are alkylboronic acids as arginase inhibitors represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof and a pharmaceutical composition comprising said compounds.

HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS

The present invention relates to heterocyclic compounds as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition comprising said compound.

NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS

The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, and its use in therapy.

Discovery of novel imidazo[4,5- b ]pyridines as potent and selective inhibitors of phosphodiesterase 10A (PDE10A)

We report the discovery of novel imidazo[4,5-b]pyridines as potent and selective inhibitors of PDE10A. The investigation began with our recently disclosed ketobenzimidazole 1, which exhibited single digit nanomolar PDE10A activity but poor oral bioavailab

HETEROBICYCLIC COMPOUNDS

Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

Cyclobutane-derived diamines: Synthesis and molecular structure

Cyclobutane diamines (i.e., cis- and trans-1,3-diaminocyclobutane, 6-amino-3-azaspiro[3.3]heptane, and 3,6-diaminospiro[3.3]heptane) are considered as promising sterically constrained diamine building blocks for drug discovery. An approach to the syntheses of their Boc-monoprotected derivatives has been developed aimed at the preparation of multigram amounts of the compounds. These novel synthetic schemes exploit classical malonate alkylation chemistry for the construction of cyclobutane rings. The conformational preferences of the cyclobutane diamine derivatives have been evaluated by X-ray diffraction and compared with the literature data on sterically constrained diamines, which are among the constituents of commercially available drugs.